Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLPT Stock Forecast 2025-2026
$11.25
Current Price
$315.72M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CLPT Price Targets
+166.7%
To High Target of $30.00
+157.8%
To Median Target of $29.00
+148.9%
To Low Target of $28.00
CLPT Price Momentum
-6.9%
1 Week Change
-14.3%
1 Month Change
+114.3%
1 Year Change
-26.9%
Year-to-Date Change
-41.5%
From 52W High of $19.22
+120.2%
From 52W Low of $5.11
📊 TOP ANALYST CALLS
Did CLPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ClearPoint Neuro is one of their latest high-conviction picks.
Latest CLPT Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CLPT has a bullish consensus with a median price target of $29.00 (ranging from $28.00 to $30.00). Currently trading at $11.25, the median forecast implies a 157.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 166.7% upside. Conversely, the most conservative target is provided by Neil Chatterji at B. Riley Securities, suggesting a 148.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLPT Analyst Ratings
2
Buy
0
Hold
0
Sell
CLPT Price Target Range
Low
$28.00
Average
$29.00
High
$30.00
Current: $11.25
Latest CLPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 25, 2025 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $28.00 |
| Apr 1, 2025 | Stifel | Mathew Blackman | Buy | Maintains | $25.00 |
| Jan 28, 2025 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $20.00 |
| Jan 21, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $30.00 |
| Aug 27, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $15.00 |
| Mar 13, 2024 | Stifel | Mathew Blackman | Buy | Reiterates | $9.00 |
| Oct 24, 2023 | Stifel | Mathew Blackman | Buy | Initiates | $8.00 |
| Aug 9, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $15.00 |
| Feb 16, 2023 | B. Riley Securities | Neil Chatterji | Buy | Reinstates | $14.00 |
| Apr 5, 2022 | B. Riley Securities | Marc Wiesenberger | Buy | Reinstates | $15.00 |
| Mar 18, 2021 | Lake Street | Frank Takkinen | Buy | Initiates | $32.00 |
| Jul 17, 2020 | B. Riley Securities | Buy | Initiates | $0.00 |
ClearPoint Neuro Inc. (CLPT) Competitors
The following stocks are similar to ClearPoint Neuro based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CLPT
ClearPoint Neuro
mkt cap
326.18M
ClearPoint Neuro Inc. (CLPT) Financial Data
ClearPoint Neuro Inc. has a market capitalization of $315.72M with a P/E ratio of 0.0x. The company generates $32.24M in trailing twelve-month revenue with a -64.5% profit margin.
Revenue growth is +11.1% quarter-over-quarter, while maintaining an operating margin of -72.6% and return on equity of -76.2%.
Valuation Metrics
Market Cap
$315.72M
Enterprise Value
$303.69M
P/E Ratio
0.0x
PEG Ratio
-18.3x
Price/Sales
9.8x
Growth & Margins
Revenue Growth (YoY)
+11.1%
Gross Margin
+60.5%
Operating Margin
-72.6%
Net Margin
-64.5%
EPS Growth
+11.1%
Financial Health
Cash/Price Ratio
+3.9%
Current Ratio
3.5x
Debt/Equity
17.2x
ROE
-76.2%
ROA
-32.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ClearPoint Neuro Inc. (CLPT) Business Model
About ClearPoint Neuro Inc.
What They Do
Develops MRI-guided systems for neurological surgeries.
Business Model
The company generates revenue by developing and commercializing advanced medical devices that enhance surgical precision in neurological procedures. Its primary offerings include real-time MRI-guided systems that assist in various interventions, such as biopsies and tumor resections, which integrate with existing MRI machinery.
Additional Information
ClearPoint Neuro is positioned at the forefront of innovation in the healthcare sector, particularly in neuroscience. Its technology not only improves surgical accuracy but also contributes to the advancement of precision medicine, making it a critical player in the treatment of neurological conditions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
115
CEO
Mr. Joseph Michael Burnett
Country
United States
IPO Year
2012
Website
www.clearpointneuro.comClearPoint Neuro Inc. (CLPT) Latest News & Analysis
Latest News
Quick Summary
Five science sectors with high potential are highlighted: brain-computer interfaces, CRISPR, organoids, programmable cell therapy, and room-temperature superconductors. Watch for breakthroughs.
Why It Matters
Emerging sectors like brain-computer interfaces and CRISPR could yield significant stock gains. Breakthroughs from major tech players may drive investor interest and market volatility.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Five notable medical instrument stocks are DXCM, IDXX, NPCE, CLPT, and FMS, indicating potential investment opportunities in this sector.
Why It Matters
The mention of these high-performing medical instrument stocks indicates potential investment opportunities and highlights sectors with strong growth prospects in healthcare.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ClearPoint Neuro, Inc. (NASDAQ:CLPT) will hold its Q1 2025 earnings conference call on May 13, 2025, at 4:30 PM ET, featuring CEO Joseph Burnett and CFO Danilo D'Alessandro.
Why It Matters
ClearPoint Neuro's upcoming earnings call may reveal key financial performance metrics and future guidance, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ClearPoint Neuro, Inc. reported Q1 2025 revenue of $8.5 million, up 11% YoY, driven by a 70% growth in navigation and therapy products. The company also received FDA clearance for ClearPoint 3.0 Software.
Why It Matters
ClearPoint Neuro's record revenue and 70% growth in navigation and therapy products signal strong market demand, innovation, and regulatory approval, likely boosting investor confidence and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
ClearPoint Neuro, Inc. (CLPT) reported a quarterly loss of $0.22 per share, worse than the expected loss of $0.15, and a decline from a loss of $0.16 per share a year earlier.
Why It Matters
ClearPoint Neuro's larger-than-expected quarterly loss signals potential operational challenges, which may lead to investor concerns about future profitability and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
ClearPoint Neuro, Inc. (NASDAQ:CLPT) has secured a note financing arrangement with Oberland Capital for up to $105 million, with $30 million funded at closing and options for additional funds by December 2026.
Why It Matters
ClearPoint Neuro's $105 million financing arrangement signals strong investor confidence and provides capital for growth, potentially enhancing its market position and driving future revenue.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About CLPT Stock
What is ClearPoint Neuro Inc.'s (CLPT) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, ClearPoint Neuro Inc. (CLPT) has a median price target of $29.00. The highest price target is $30.00 and the lowest is $28.00.
Is CLPT stock a good investment in 2025?
According to current analyst ratings, CLPT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLPT stock?
Wall Street analysts predict CLPT stock could reach $29.00 in the next 12 months. This represents a 157.8% increase from the current price of $11.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ClearPoint Neuro Inc.'s business model?
The company generates revenue by developing and commercializing advanced medical devices that enhance surgical precision in neurological procedures. Its primary offerings include real-time MRI-guided systems that assist in various interventions, such as biopsies and tumor resections, which integrate with existing MRI machinery.
What is the highest forecasted price for CLPT ClearPoint Neuro Inc.?
The highest price target for CLPT is $30.00 from Frank Takkinen at Lake Street, which represents a 166.7% increase from the current price of $11.25.
What is the lowest forecasted price for CLPT ClearPoint Neuro Inc.?
The lowest price target for CLPT is $28.00 from Neil Chatterji at B. Riley Securities, which represents a 148.9% increase from the current price of $11.25.
What is the overall CLPT consensus from analysts for ClearPoint Neuro Inc.?
The overall analyst consensus for CLPT is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $29.00.
How accurate are CLPT stock price projections?
Stock price projections, including those for ClearPoint Neuro Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 2:39 AM UTC